Prostate cancer: Provenge as immunotherapeutic agent in the form of dendritic cell therapy in hormone resistant prostate cancer provides significantly longer survival. 3-year survival is 38% and improves median survival by 4 months (20%). A highly significant result. Phase III study shows. FDA approval for Provenge now. Article updated June 22, 2011

Provenge is a form of dendritic cell therapy in hormone resistant prostate cancer provides significantly longer survival. 3-year survival is 38% and improves median survival by 4 months (20%). A highly significant result. Phase III study shows. FDA now has approval to Provenge for use in patients with hormone-resistant prostate cancer. Article updated May 1, 2010